Recently, the chimeric mouse–human monoclonal Epidermal Growth Factor Receptor (EGFR) antibody Cetuximab (Erbitux, Merck KGaA, Darmstadt, Germany) was approved by the Food and Drug Administration (FDA) for the treatment of locally advanced HNSCC, in combination with radiation, as well as for recurrent/metastatic diseases, together with other chemotherapeutics [7]. Here, EGFR is linked to head and neck squamous cell carcinoma.